The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Open accessAbstract
A pathological hallmark of Alzheimer's disease is an accumulation of insoluble plaque containing the amyloid-beta peptide of 40-42 amino acid residues. Prefibrillar, soluble oligomers of amyloid-beta have been recognized to be early and key intermediates in Alzheimer's-disease-related synaptic dysfunction. At nanomolar concentrations, soluble amyloid-beta oligomers block hippocampal long-term potentiation, cause dendritic spine retraction from pyramidal cells and impair rodent spatial memory. Soluble amyloid-beta oligomers have been prepared from chemical syntheses, transfected cell culture supernatants, transgenic mouse brain and human Alzheimer's disease brain. Together, these data imply a high-affinity cell-surface receptor for soluble amyloid-beta oligomers on neurons-one that is central to the pathophysiological process in Alzheimer's disease. Here we identify the cellular prion protein (PrP(C)) as an amyloid-beta-oligomer receptor by expression cloning. Amyloid-beta oligomers bind with nanomolar affinity to PrP(C), but the interaction does not require the infectious PrP(Sc) conformation. Synaptic responsiveness in hippocampal slices from young adult PrP null mice is normal, but the amyloid-beta oligomer blockade of long-term potentiation is absent. Anti-PrP antibodies prevent amyloid-beta-oligomer binding to PrP(C) and rescue synaptic plasticity in hippocampal slices from oligomeric amyloid-beta. Thus, PrP(C) is a mediator of amyloid-beta-oligomer-induced synaptic dysfunction, and PrP(C)-specific pharmaceuticals may have therapeutic potential for Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the Aβ binding candidates, cellular prion protein (PrPc) represents the most studied, either alone or through a complex with mGluR5 [37, 62, 72, 79].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most studied binding partner is the PrPc, which through a cascade involving a complex with mGluR5 may lead to toxicity independently or via tau [37, 62, 72, 79].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredIn the citing paper
“Aβ binds to α7 nicotinic acetylcholine receptors (α7 nAChRs) and to metabotropic glutamate receptors, in particular mGluR5 [31–33].”
From ApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease (2017) · cites this paper as [33]
In the citing paper
“A genome-wide association study (GWAS) identified PrPC as a potential high-affinity receptor for oAβ [87].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [87]
In the citing paper
“Subsequent studies showed that oAβ, especially high-molecular weight oligomers [88], preferentially bind to PrPC within an N-terminal 95-111aa segment [87].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [87]
In the citing paper
“oligomer binding is significantly reduced in PrPC knock-out cells (Lauren et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lauren et al., 2009
In the citing paper
“Aβ oligomers bind with nanomolar affinity to cellular prion protein (PrPC) and that anti-PrP antibodies reduce oligomer binding to neurons and rescue synaptic plasticity (Lauren et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lauren et al., 2009
In the citing paper
“explaining the finding that knocking-down these proteins or adding antibodies against their extracellular domains blocks the accumulation of ADDL clusters (“hotspots”) at synapses (De Felice et al., 2007; Decker et al., 2010a; Lauren et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lauren et al., 2009
In the citing paper
“PrPC binds synthetic Aβ oligomers with high affinity and plays a role in the oligomer-mediated inhibition of LTP (17).”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [17]
In the citing paper
“In an elegant study Lauren et al. (17) reported that PrPC mediates the Aβ oligomer-induced hippocampal synaptic plasticity impairment.”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [17]
In the citing paper
“The 22 °C-Aβ oligomers impaired recognition memory in both Prnp +/+ and Prnp 0/0 mice (Fig. 4C).”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [17]
In the citing paper
“When amyloid-β oligomers bind to PrPc, long-term potentiation and the formation of new memories are disrupted [129,130,131].”
From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2004) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,722
Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein
Büeler, H., Fischer, M., Lang, Y., Bluethmann, H., Lipp, H., DeArmond, S. J., Prusiner, S. B., Aguet, M., & Weissmann, C. (1992) · Nature · doi:10.1038/356577a0 · Cited by 1,676
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,002
The Cellular Prion Protein Increases the Uptake and Toxicity of TDP-43 Fibrils
Scialò, C., Celauro, L., Zattoni, M., Tran, T. H., Bistaffa, E., Moda, F., Kammerer, R., Buratti, E., & Legname, G. (2021) · Viruses · doi:10.3390/v13081625 · Cited by 32
Five Questions on Prion Diseases
Aguzzi, A., & Zhu, C. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002651 · Cited by 32
Natural Amyloid-Beta Oligomers Acutely Impair the Formation of a Contextual Fear Memory in Mice
Kittelberger, K. A., Piazza, F., Tesco, G., & Reijmers, L. G. J. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029940 · Cited by 35
Gabrielli, M., Tozzi, F., Verderio, C., & Origlia, N. (2022) · Cells · doi:10.3390/cells12010063 · Cited by 34
Fang, X. T., Eriksson, J., Antoni, G., Yngve, U., Cato, L., Lannfelt, L., Sehlin, D., & Syvänen, S. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.10.009 · Cited by 31
Lackie, R. E., Marques-Lopes, J., Ostapchenko, V. G., Good, S. C., Choy, W., van Oosten‐Hawle, P., Pasternak, S., Prado, V. F., & Prado, M. A. M. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01013-5 · Cited by 32
Prion Protein Biology Through the Lens of Liquid-Liquid Phase Separation
Agarwal, A., & Mukhopadhyay, S. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167368 · Cited by 33
Recent advances of small molecule JNK3 inhibitors for Alzheimer’s disease
Qin, P., Ran, Y., Liu, Y., Wei, C., Luan, X., Niu, H., Peng, J., Sun, J., & Wu, J. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106090 · Cited by 31
Mechanisms of prion-induced toxicity
Mercer, R. C. C., & Harris, D. A. (2022) · Cell and Tissue Research · doi:10.1007/s00441-022-03683-0 · Cited by 31
Octarepeat region flexibility impacts prion function, endoproteolysis and disease manifestation
Lau, A., McDonald, A. J., Daude, N., Mays, C. E., Walter, É., Aglietti, R., Mercer, R. C. C., Wohlgemuth, S. L., van der Merwe, J., Yang, J., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404588 · Cited by 31
Zhang, D., Qi, Y., Klyubin, I. V., Ondrejčák, T., Sarell, C. J., Cuello, A. C., Collinge, J., & Rowan, M. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.03.036 · Cited by 32
Long-Term Statin Therapy and CSF Cholesterol Levels: Implications for Alzheimer’s Disease
Evans, B. A., Evans, J. E., Baker, S. P., Kane, K., Swearer, J. M., Hinerfeld, D. A., Caselli, R. J., Rogaeva, E. A., George‐Hyslop, P. S., Moonis, M., et al. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000221835 · Cited by 31
Neuroimmunoendocrine Regulation of the Prion Protein in Neutrophils
Mariante, R. M., Nóbrega, A., Martins, R. A. P., Areal, R. B., Bellio, M., & Linden, R. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.394924 · Cited by 30
Alier, K. A., Ma, L., Yang, J., Westaway, D. A., & Jhamandas, J. H. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.4367-11.2011 · Cited by 30
Prion Protein Accumulation in Lipid Rafts of Mouse Aging Brain
Agostini, F., Dotti, C. G., Pérez‐Cañamás, A., Ledesma, M. D., Benetti, F., & Legname, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074244 · Cited by 30
Burns, L. H., & Wang, H.-Y. (2017) · Neuroimmunology and Neuroinflammation · doi:10.20517/2347-8659.2017.50 · Cited by 30
Aβ pathology downregulates brain mGluR5 density in a mouse model of Alzheimer
Lee, M., Lee, H., Park, I. S., Park, J. A., Kwon, Y., Ryu, Y. H., Kim, C. H., Kang, J. H., Hyun, I. Y., Lee, K. C., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.003 · Cited by 30
Mattei, V., Manganelli, V., Martellucci, S., Capozzi, A., Mantuano, E., Longo, A., Ferri, A., Garofalo, T., Sorice, M., & Misasi, R. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14891 · Cited by 30
Cellular Prion Protein Mediates α‐Synuclein Uptake, Localization, and Toxicity In Vitro and In Vivo
Thom, T., Schmitz, M., Fischer, A., Correia, A., Correia, S., Llorens, F., Pique, A., Möbius, W., Domingues, R., Zafar, S., et al. (2022) · Movement Disorders · doi:10.1002/mds.28774 · Cited by 30
Overview on peptide-based electrochemical biosensors
Liu, G., Li, Y., Liu, M., Cheng, J., Yang, S., Gao, F., & Liu, L. (2023) · International Journal of Electrochemical Science · doi:10.1016/j.ijoes.2023.100395 · Cited by 30
Alzheimer's Disease and Prion Protein
Zhou, J. (2013) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2013.v2.2.35 · Cited by 31
Chen, R.-J., Chang, W.-W., Lin, Y., Cheng, P., & Chen, Y. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400085q · Cited by 30
Hamada, T., Morita, M., Kishimoto, Y., Komatsu, Y., Vestergaard, M. C. M., & Takagi, M. (2009) · The Journal of Physical Chemistry Letters · doi:10.1021/jz900106z · Cited by 30
Roles of the cellular prion protein in the regulation of cell-cell junctions and barrier function
Petit, C. S. V., Besnier, L., Morel, É., Rousset, M., & Thenet, S. (2013) · Tissue Barriers · doi:10.4161/tisb.24377 · Cited by 30
McDonald, A. J., & Millhauser, G. L. (2014) · Prion · doi:10.4161/pri.28796 · Cited by 30
Domains of STIP1 responsible for regulating PrPC-dependent amyloid-β oligomer toxicity
Maciejewski, A., Ostapchenko, V. G., Beraldo, F. H., Prado, V. F., Prado, M. A. M., & Choy, W. (2016) · Biochemical Journal · doi:10.1042/bcj20160087 · Cited by 31
Barucker, C., Bittner, H. J., Chang, P. K. ‐., Cameron, S., Hancock, M. A., Liebsch, F., Hossain, S., Harmeier, A., Shaw, H. S., Charron, F. M., et al. (2015) · Scientific Reports · doi:10.1038/srep15410 · Cited by 32
Drebrin in Alzheimer’s Disease
Ishizuka, Y., & Hanamura, K. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-4-431-56550-5_12 · Cited by 32
Wang, J. S.-H., Whitehead, S. N., & Yeung, K. K. ‐. (2018) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-018-1896-z · Cited by 31
Anti‐PrPC antibody rescues cognition and synapses in transgenic alzheimer mice
Cox, T. O., Gunther, E. C., Brody, A. H., Chiasseu, M. T., Stoner, A., Smith, L. M., Haas, L. T., Hammersley, J., Rees, G., Dosanjh, B., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.730 · Cited by 33
Self-citationImmunotherapy against Prion Disease
Ma, Y., & Ma, J. (2020) · Pathogens · doi:10.3390/pathogens9030216 · Cited by 31
Dinamarca, M. C., Luca, M. D., Godoy, J. A., & Inestrosa, N. C. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.107 · Cited by 32
Breaking the Code of Amyloid- β Oligomers
Lesné, S. (2013) · International Journal of Cell Biology · doi:10.1155/2013/950783 · Cited by 29
Simoni, E., Serafini, M. M., Bartolini, M., Caporaso, R., Pinto, A., Necchi, D., Fiori, J., Andrisano, V., Minarini, A., Lanni, C., et al. (2015) · ChemMedChem · doi:10.1002/cmdc.201500422 · Cited by 29
Johnson, R. D., Steel, D. G., & Gafni, A. (2014) · Protein Science · doi:10.1002/pro.2479 · Cited by 29
Heiss, J. K., Barrett, J., Yu, Z., Haas, L. T., Kostylev, M. A., & Strittmatter, S. M. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhw188 · Cited by 30
Self-citationLeighton, P. L. A., & Allison, W. T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160361 · Cited by 31
Mehrabian, M., Hildebrandt, H., & Schmitt‐Ulms, G. (2016) · ASN NEURO · doi:10.1177/1759091416679074 · Cited by 30
Zhang, J., Yin, Y., Ji, Z., Cai, Z., Zhao, B., Li, J., Tan, M., & Guo, G. (2017) · Neural Plasticity · doi:10.1155/2017/8197085 · Cited by 29
Comoy, E. E., Mikol, J., Jaffré, N., Lebon, V., Levavasseur, E., Streichenberger, N., Sumian, C. C., Perret‐Liaudet, A., Éloit, M., Andréoletti, O., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01347-0 · Cited by 29
Castle, A. R., Daude, N., Gilch, S., & Westaway, D. A. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006367 · Cited by 29
A Spectroscopic Marker for Structural Transitions Associated with Amyloid-β Aggregation
Das, A., Gupta, A., Hong, Y., Carver, J. A., & Maiti, S. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00113 · Cited by 29
Martínez-Valbuena, I., Valenti‐Azcarate, R., Amat, I., Marcilla, I., Martí‐Andrés, G., Caballero, M. C., Riverol, M., Tuñon, M.-T., Fraser, P. E., & Luquín, M. R. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01171-0 · Cited by 30
Prion Protein Modulates Monoaminergic Systems and Depressive-like Behavior in Mice
Beckman, D., Santos, L. E., Americo, T. A., Ledo, J. H., Mello, F. G. D., & Linden, R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.666156 · Cited by 30
Prion protein and its role in signal transduction
Didonna, A. (2013) · Cellular & Molecular Biology Letters · doi:10.2478/s11658-013-0085-0 · Cited by 29
Trillo, E. M., & Sempou, E. (2009) · Prion · doi:10.4161/pri.3.3.9651 · Cited by 34
Endogenous Prion Protein Attenuates Experimentally Induced Colitis
Martin, G. R., Keenan, C. M., Sharkey, K. A., & Jirik, F. R. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.07.025 · Cited by 29
Prion protein oligomer and its neurotoxicity
Huang, P., Lian, F., Wen, Y., Guo, C., & Lin, D. (2013) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt037 · Cited by 29
Pinnock, E. C., Jovanovic, K., Pinto, M. G., Ferreira, E., Dias, B. D. C., Penny, C. B., Knackmuss, S. H. J., Reusch, U., Little, M., Schätzl, H. M., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150482 · Cited by 29
Lin, D., Luo, Y., Wu, S., Ma, Q., Wei, G., & Yang, X. (2014) · Langmuir · doi:10.1021/la4048165 · Cited by 29
Monomeric amyloid-β reduced amyloid-β oligomer-induced synapse damage in neuronal cultures
Bate, C., & Williams, A. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.12.007 · Cited by 30
Age, Neuropathology, and Dementia
Chen, L.-W. (2009) · New England Journal of Medicine · doi:10.1056/nejmc091346 · Cited by 29
Hu, T., Wang, S., Chen, C., Sun, J., & Yang, X. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.6b04950 · Cited by 28
Subtype and regional regulation of prion biomarkers in sporadic C reutzfeldt– J akob disease
Llorens, F., Zafar, S., Ansoleaga, B., Shafiq, M., Blanco, R., Carmona, M., Grau‐Rivera, O., Nos, C., Gelpí, E., del Rı́o, J. A., et al. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12175 · Cited by 28
Protein aggregation and prionopathies
Renner, M. L., & Melki, R. (2014) · Pathologie Biologie · doi:10.1016/j.patbio.2014.01.003 · Cited by 31
A 2cM genome-wide scan of European Holstein cattle affected by classical BSE
Murdoch, B. M., Clawson, M. L., Laegreid, W. W., Stothard, P., Settles, M. L., McKay, S., Prasad, A., Wang, Z., Moore, S. S., & Williams, J. L. (2010) · BMC Genetics · doi:10.1186/1471-2156-11-20 · Cited by 28
The prion protein constitutively controls neuronal store-operated Ca2+ entry through Fyn kinase
Mario, A. D., Castellani, A., Peggion, C., Massimino, M. L., Lim, D., Hill, A. F., Sorgato, M. C., & Bertoli, A. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00416 · Cited by 28
Role of cellular prion protein in interneuronal amyloid transmission
del Rı́o, J. A., Ferrer, I., & Gavı́n, R. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.03.001 · Cited by 30
Nanomechanical insights: Amyloid beta oligomer-induced senescent brain endothelial cells
Kulkarni, T., Angom, R. S., Das, P., Bhattacharya, S., & Mukhopadhyay, D. (2019) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2019.183061 · Cited by 29
Poejo, J., Salazar, J., Mata, A. M., & Gutiérrez‐Merino, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094976 · Cited by 28
Extracellular vesicles with diagnostic and therapeutic potential for prion diseases
Khadka, A., Spiers, J. G., Cheng, L., & Hill, A. F. (2022) · Cell and Tissue Research · doi:10.1007/s00441-022-03621-0 · Cited by 29
Alzheimer’s Disease and Neuronal Network Activity
Gleichmann, M., & Mattson, M. P. (2009) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8100-3 · Cited by 29
Insoluble cellular prion protein and its association with prion and Alzheimer diseases
Zou, W., Zhou, X., Yuan, J., & Xiao, X. (2011) · Prion · doi:10.4161/pri.5.3.16894 · Cited by 28
Cellular Prion Protein Mediates Toxic Signaling of Amyloid Beta
Resenberger, U. K., Winklhofer, K. F., & Tatzelt, J. (2011) · Neurodegenerative Diseases · doi:10.1159/000332596 · Cited by 28
Anti-LRP/LR specific antibodies and shRNAs impede amyloid beta shedding in Alzheimer's disease
Jovanovic, K., Gonsalves, D., Dias, B. D. C., Moodley, K., Reusch, U., Knackmuss, S. H. J., Penny, C. B., Weinberg, M. S., Little, M., & Weiss, S. F. T. (2013) · Scientific Reports · doi:10.1038/srep02699 · Cited by 28
Cronier, S., Carimalo, J., Schaeffer, B., Jaumain, E., Béringue, V., Miquel, M., Laude, H., & Peyrin, J. (2012) · The FASEB Journal · doi:10.1096/fj.11-201772 · Cited by 28
Prion Protein PRNP: A New Player in Innate Immunity? The Aβ Connection
Lathe, R., & Darlix, J. (2017) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-170037 · Cited by 28
Ghodrati, F., Mehrabian, M., Williams, D., Halgas, O., Bourkas, M. E. C., Watts, J. C., PAI, E. F., & Schmitt‐Ulms, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-26685-x · Cited by 28
The Role of Exosomes/Extracellular Vesicles in Neural Signal Transduction
Kawahara, H., & Hanayama, R. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00167 · Cited by 28
Cell Clearing Systems Bridging Neuro-Immunity and Synaptic Plasticity
Limanaqi, F., Biagioni, F., Busceti, C. L., Ryskalin, L., Soldani, P., Frati, A., & Fornai, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092197 · Cited by 28
Yeast Models for Amyloids and Prions: Environmental Modulation and Drug Discovery
Chernova, T. A., Chernoff, Y. O., & Wilkinson, K. D. (2019) · Molecules · doi:10.3390/molecules24183388 · Cited by 29
Furukawa, T., Nikaido, Y., Shimoyama, S., Masuyama, N., Notoya, A., & Ueno, S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.777404 · Cited by 27
Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease
Li, X., Tsolis, K. C., Koper, M. J., Ronisz, A., Ospitalieri, S., von Arnim, C. A. F., Vandenberghe, R., Tousseyn, T., Scheuerle, A., Economou, A., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12345 · Cited by 27
Efficient enzyme‐free isolation of brain‐derived extracellular vesicles
Matamoros‐Angles, A., Karadjuzovic, E., Mohammadi, B., Song, F., Brenna, S., Meister, S. C., Siebels, B., Voß, H., Seuring, C., Ferrer, I., et al. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70011 · Cited by 27
Guan, P.-P., Yu, X., Zou, Y.-H., & Wang, P. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0294-1 · Cited by 27
Legname, G., & Scialò, C. (2020) · Prion · doi:10.1080/19336896.2020.1854034 · Cited by 29
Accumulation of cellular prion protein within β‐amyloid oligomer plaques in aged human brains
Takahashi, R. H., Yokotsuka, M., Tobiume, M., Sato, Y., Hasegawa, H., Nagao, T., & Gouras, G. K. (2021) · Brain Pathology · doi:10.1111/bpa.12941 · Cited by 27
Aß Pathology and Neuron–Glia Interactions: A Synaptocentric View
Huffels, C. F. M., Middeldorp, J., & Hol, E. M. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03699-6 · Cited by 29
Differently Selected d -Enantiomeric Peptides Act on Different Aβ Species
Bartnik, D., Funke, S. A., Andrei‐Selmer, L., Bacher, M., Dodel, R. C., & Willbold, D. (2009) · Rejuvenation Research · doi:10.1089/rej.2009.0924 · Cited by 27
Rubel, A. A., Belashova, T. A., Antonets, K. S., Chernoff, Y. O., & Galkin, A. P. (2013) · Prion · doi:10.4161/pri.26867 · Cited by 27
Vaisid, T., Barnoy, S., & Kosower, N. S. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.07.010 · Cited by 27
The Transcription Factor XBP1 in Memory and Cognition: implications in Alzheimer’s Disease
Cissé, M., Duplan, E., & Checler, F. (2016) · Molecular Medicine · doi:10.2119/molmed.2016.00229 · Cited by 28
Willén, K. I., Sroka-Oleksiak, A., Takahashi, R. H., & Gouras, G. K. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170262 · Cited by 28
Role of ASIC1a in Aβ-induced synaptic alterations in the hippocampus
Mango, D., & Nisticò, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.016 · Cited by 27
Molecular chaperones biochemistry and role in neurodegenerative diseases
Châari, A. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.02.148 · Cited by 27
Guzmán, B. C., Kim, S., Chawdhary, B., Peppercorn, K., Tate, W. P., Waldvogel, H. J., Faull, R. L. M., Montgomery, J. M., & Kwakowsky, A. (2020) · Molecules · doi:10.3390/molecules25030693 · Cited by 27
Huang, Y., Zhang, B., Yuan, L., & Liu, L. (2021) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2021.129697 · Cited by 27
The cellular prion protein and its role in Alzheimer disease
Velayos, J. L., Irujo, A., Cuadrado‐Tejedor, M., Paternain, B., Moleres, F. J., & Ferrer, V. (2009) · Prion · doi:10.4161/pri.3.2.9135 · Cited by 27
Froestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 27
Polymer–Metal Composite Healthcare Materials: From Nano to Device Scale
Wong, W., Lai, C.-H. N., Cheng, W., Tung, L.-H., Chang, R. C., & Leung, F. K. (2022) · Journal of Composites Science · doi:10.3390/jcs6080218 · Cited by 26
Intraneuronally injected amyloid beta inhibits long-term potentiation in rat hippocampal slices
Nomura, I., Takechi, H., & Kato, N. (2012) · Journal of Neurophysiology · doi:10.1152/jn.00589.2011 · Cited by 27
Immunoglobulin Light Chain Systemic Amyloidosis
Dispenzieri, A. A., & Merlini, G. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_15 · Cited by 26
An ancient conserved role for prion protein in learning and memory
Leighton, P. L. A., Nadolski, N. J., Morrill, A., Hamilton, T. J., & Allison, W. T. (2018) · Biology Open · doi:10.1242/bio.025734 · Cited by 27
Immune-Related Hub Genes and the Competitive Endogenous RNA Network in Alzheimer’s Disease
Xu, H., & Jia, J. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200081 · Cited by 26
Alzheimer’s protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity
Limegrover, C. S., LeVine, H., Izzo, N. J., Yurko, R., Mozzoni, K., Rehak, C., Sadlek, K., Safferstein, H., & Catalano, S. M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15212 · Cited by 24
Squitti, R., Reale, G., Tondolo, V., Crescenti, D., Bellini, S., Moci, M., Caliandro, P., Padua, L., & Rongioletti, M. C. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076867 · Cited by 26
β-amyloid oligomers and prion protein
Forloni, G., & Balducci, C. (2011) · Prion · doi:10.4161/pri.5.1.14367 · Cited by 26
Structural and mechanistic commonalities of amyloid-β and the prion protein
Dias, B. D. C., Jovanovic, K., Gonsalves, D., & Weiss, S. F. T. (2011) · Prion · doi:10.4161/pri.5.3.17025 · Cited by 26
Role of Small Oligomers on the Amyloidogenic Aggregation Free-Energy Landscape
He, X., Giurleo, J. T., & Talaga, D. S. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.10.019 · Cited by 26
Jovanovic, K., Loos, B., Dias, B. D. C., Penny, C. B., & Weiss, S. F. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100373 · Cited by 26
Metadata
- Authors
- Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M.
- Affiliations
- Yale University (US)
- Corresponding author
- Strittmatter, Stephen M.
- Venue
- Nature
- Published
- 2009-02
- Volume
- 457
- Issue
- 7233
- Pages
- 1128-1132
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2748841
- OpenAlex
- W2171526610
- Cited by
- 1,560
- References
- 37
- Citations by year
- 2026: 46 · 2025: 45 · 2024: 50 · 2023: 52 · 2022: 87 · 2021: 82 · 2020: 85 · 2019: 71 · 2018: 108 · 2017: 117 · 2016: 103 · 2015: 98 · 2014: 104 · 2013: 116 · 2012: 119
- FWCI
- 87.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- U.S. Public Health Service (5T32GN07205)
- National Institute on Drug Abuse (P30DA018343)
- National Institute of Neurological Disorders and Stroke (R01NS042304, R01NS039962, R37NS033020)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- cellular prion protein, amyloid-beta oligomers, Alzheimer's disease, synaptic plasticity, long-term potentiation, cell surface receptors, lipid rafts, hippocampus, anti-PrP antibodies, prion disease, expression cloning, neurotoxicity, spatial memory, neuroprotection, neurodegeneration
- MeSH terms
- Alzheimer Disease, Amyloidosis, Animals, Chlorocebus aethiops, Hippocampus, Humans, Mice, Inbred C57BL, Neuronal Plasticity, Neurons, Peptide Fragments, Prions, Protein Binding, Receptors, Cell Surface, Synapses, Amyloid beta-Peptides, Long-Term Potentiation, COS Cells, Mice, Amyloid Precursor Protein Secretases, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
